Group
Anti-PDGFRα mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | Anti-PDGFRα antibody |
| Drugs in group | Olaratumab |
Location
Treated site
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Data: details & interpretation
“One prospective study[1] included nine patients treated with olaratumab and SRT (wmFUP: 24mo). The patients received SRT to the brain, lung, head and neck region or pelvis. Olaratumab was paused in only one patient. No hgRTAEs were reported.
In summary, data remains too limited to draw conclusions.”
References (1)
- 1. Looman EL, Kroeze SGC, Schaule J, et al. Adverse Events After Metastases-Directed Stereotactic Radiotherapy and Biological Cancer Therapy. JAMA Netw Open. 2026/01/02/ 2026;9(1):e2553809. doi:10.1001/jamanetworkopen.2025.53809
Radiobiological rationale for RT–drug interaction
No radiosensitization demonstrated (reduced microvessel density without tumor growth-delay benefit), though evidence is very limited (Song et al., EBioMedicine, 2019).
The data above refer to patients treated with Anti-PDGFRα mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.